Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Go back to Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 6.11 -0.08 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.19 | 52 Week High | $7.49 | |||
| Open | $6.20 | 52 Week Low | $2.61 | |||
| Day High | $6.23 | P/E | N/A | |||
| Day Low | $6.00 | EPS | $-1.10 | |||
| Volume | 383,752 | |||||
